194 related articles for article (PubMed ID: 37403477)
21. Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States.
Pizzicato LN; Vadhariya A; Birt J; Ketkar AG; Bolce R; Grabner M; Pepe RS; Walsh JA
J Manag Care Spec Pharm; 2023 Jan; 29(1):24-35. PubMed ID: 36318701
[No Abstract] [Full Text] [Related]
22. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
[TBL] [Abstract][Full Text] [Related]
23. Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study.
Grellmann C; Dombrowsky W; Fabricius V; Suruki R; Sheahan A; Joeres L
Adv Ther; 2021 Jan; 38(1):366-385. PubMed ID: 33128201
[TBL] [Abstract][Full Text] [Related]
24. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
25. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
[TBL] [Abstract][Full Text] [Related]
26. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
Sruamsiri R; Iwasaki K; Tang W; Mahlich J
BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
Duffin KC; Mazzuoccolo LD; Cura MJ; Esposito M; Fernandez AP; Gisondi P; Giunta A; Hillary T; Piaserico S; Solomon JA; Merola JF
J Rheumatol; 2023 Jan; 50(1):131-143. PubMed ID: 36319014
[TBL] [Abstract][Full Text] [Related]
28. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
Gargiulo L; Ibba L; Malagoli P; Balato A; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Megna M; Mercuri SR; Travaglini M; Costanzo A; Narcisi A
Front Immunol; 2023; 14():1341708. PubMed ID: 38274801
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
Saeki H; Nakagawa H; Ishii T; Morisaki Y; Aoki T; Berclaz PY; Heffernan M
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1148-55. PubMed ID: 25355284
[TBL] [Abstract][Full Text] [Related]
30. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
31. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: Results from the Medical Data Vision claims database.
Morita A; Kotowsky N; Gao R; Shimizu R; Okubo Y
J Dermatol; 2021 Oct; 48(10):1463-1473. PubMed ID: 34212422
[TBL] [Abstract][Full Text] [Related]
32. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan.
Kishimoto M; Komine M; Kamiya K; Sugai J; Mieno M; Ohtsuki M
J Dermatol; 2020 Jan; 47(1):33-40. PubMed ID: 31696543
[TBL] [Abstract][Full Text] [Related]
33.
Larid G; Delwail A; Dalle T; Vasseur P; Silvain C; Jégou JF; Morel F; Lecron JC; Gervais E
Front Immunol; 2022; 13():993363. PubMed ID: 36426370
[TBL] [Abstract][Full Text] [Related]
34. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
[TBL] [Abstract][Full Text] [Related]
35. Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan.
Miyachi H; Konishi T; Kumazawa R; Matsui H; Shimizu S; Fushimi K; Matsue H; Yasunaga H
J Am Acad Dermatol; 2022 Jun; 86(6):1266-1274. PubMed ID: 34116101
[TBL] [Abstract][Full Text] [Related]
36. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies.
Novelli L; Chimenti MS; Chiricozzi A; Perricone R
Autoimmun Rev; 2014 Jan; 13(1):64-9. PubMed ID: 24021172
[TBL] [Abstract][Full Text] [Related]
37. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors.
Wright S; Alloo A; Strunk A; Garg A
J Am Acad Dermatol; 2020 Aug; 83(2):382-387. PubMed ID: 32289401
[TBL] [Abstract][Full Text] [Related]
38. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
Xie Y; Liu Y
Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry.
Kojanova M; Hugo J; Velackova B; Cetkovska P; Fialova J; Dolezal T; Tichy M; Gkalpakiotis S;
J Dermatolog Treat; 2022 Sep; 33(6):2827-2837. PubMed ID: 35635185
[TBL] [Abstract][Full Text] [Related]
40. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
